AstraZeneca Stock Looks Cheap On Cash Flow Value

With inflation signals diverging across regions, energy prices reacting to geopolitical tensions, and central banks keeping policy decisions closely tied to incoming data, investors are paying more attention to what really drives value, cash generation and what they are paying for it. The Undervalued Stocks Based On Cash Flows screener focuses on companies where discounted cash flow estimates from SWS suggest the share price sits below fair value. That combination, underpinned by cash flow potential rather than market headlines, can appeal to patient, value-oriented investors. This article highlights three stocks from the screener that stand out on those terms.

AstraZeneca (LSE:AZN)

Overview: AstraZeneca is a global biopharmaceutical company based in Cambridge, UK, that discovers, develops, manufactures, and sells prescription medicines across oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and immune therapies, and rare diseases.

Operations: AstraZeneca generates about $60.4b in revenue, primarily from its pharmaceuticals segment.

Market Cap: £194.9b

AstraZeneca draws attention because its large, diversified drug portfolio and steady flow of new oncology and specialty medicine approvals sit alongside a robust late stage pipeline and expanding presence in markets such as China and Latin America. At the same time, the stock screens as materially undervalued against Simply Wall St’s cash flow estimates, even though analysts already factor in solid earnings growth and strong returns on equity. The recent licensing deal for Zegfrovy and progress with drugs like Enhertu and TRUQAP highlight how the company continues to add potential future revenue sources. However, investors also need to weigh risks related to high R&D spend, sizable debt and heavy reliance on blockbuster drugs facing pricing and patent pressure.

AstraZeneca’s cash flow story looks out of sync with its current share price. The real question is how that gap could close as the pipeline matures and risks play out in practice, so review the DCF valuation analysis for AstraZeneca.

Foresight Group Holdings (LSE:FSG)

Overview: Foresight Group Holdings is a London based asset manager that invests in infrastructure, renewable energy projects, private equity and venture backed companies, offering both institutional and retail investors access to real assets and sustainable investment strategies across several regions.

Operations: Foresight Group Holdings generates about £114.8m in revenue from Real Assets and £50.1m from Private Equity, with most revenue coming from the United Kingdom and Australia.

Market Cap: £519.1m

Foresight Group Holdings earns attention in this screener because it combines strong reported profitability with rapid asset gathering in areas like renewable energy and infrastructure, while still trading below Simply Wall St’s estimate of fair value and at a lower P/E than many peers. Earnings growth has been solid, margins are high, and ongoing share buybacks reduce the share count, which can lift earnings per share over time. At the same time, the business leans on performance fees, higher risk external borrowing and concentrated exposure to UK and European regulation, so earnings can be sensitive to policy shifts and market cycles. That mix of quality, growth potential and real but manageable risks is what makes the fuller Foresight story worth a closer look.

Foresight Group’s high margins, fee potential and share buybacks paint a growth story that the current valuation may not fully reflect, so review the DCF valuation analysis for Foresight Group Holdings to see what the market could be missing.

BAE Systems (LSE:BA.)

Overview: BAE Systems is a London headquartered defense and aerospace company that supplies military aircraft, ships, combat vehicles, munitions, electronic warfare systems, space hardware, and cyber security services to governments and defense customers around the world.

Operations: BAE Systems generates around £7.5b from Electronic Systems, £7.4b from Air, £6.6b from Maritime, £5.0b from Platforms & Services, £2.4b from Cyber & Intelligence and £52m from Head Quarter (HQ), adjusted for intra group sales of £592m.

Market Cap: £51.4b

Investors looking at BAE Systems are being offered a large defense contractor with a £75b order backlog and exposure to areas like electronic warfare, drones and space systems. Analysts expect its revenue growth to run ahead of the wider UK market, while the stock trades below Simply Wall St’s estimate of future cash flow value. That appeal sits alongside real trade offs, including reliance on long term government contracts, supply chain and capacity bottlenecks, ESG pushback, and a balance sheet funded entirely by higher risk external borrowing. Recent contract wins in electronic warfare, active protection systems and space imagery show how its pipeline is evolving, but the full picture of how growth, valuation and risk fit together is more nuanced than headline metrics suggest.

BAE Systems’ accelerating order backlog and cash flow value story can look out of sync with its share price, so walk through the DCF valuation analysis for BAE Systems to see what the balance sheet is quietly signaling.

The three stocks covered are only a starting point, as the full Undervalued Stocks Based On Cash Flows screener surfaced 36 more companies where discounted cash flow estimates flag a similar gap between price and potential. Use Simply Wall St to identify and analyze the specific catalysts, cash flow profiles and narratives that matter most to you, so you can focus on the highest conviction ideas from that list.

Take Control of Your Investment Journey

If AstraZeneca or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before The Crowd Moves?

Fresh stock ideas can start breaking out while attention lags and momentum flies elsewhere. Explore these under the radar picks before the data goes stale.

• Spot companies quietly building strength with the list of solid balance sheet and fundamentals (20 results) and see which balance sheets might hold up when conditions shift.
• Target income opportunities by scanning the 3 dividend fortresses and find high yielding stocks that still keep financial resilience front and center.
• Track long term structural trends by checking the 34 power grid technology and infrastructure stocks and follow companies tied to critical grid upgrades while they are still under the radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com